To assess the relative BA of a low-strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents after single dose administration and to assess BE of a regular strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents at steady state in men with prostate cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508150-26-00

Acronym

67652000PCR1001

Enrollment

Registered

2024-05-06

Start date

2020-11-26

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic castration-resistant prostate cancer (mCRPC)

None listed

Sex/Gender

Male

Age

18 Years to No maximum

Netherlands, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026